These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27455953)

  • 21. Adoptive B-cell transfer mouse model of human myeloma.
    Tompkins VS; Rosean TR; Holman CJ; DeHoedt C; Olivier AK; Duncan KM; Jing X; Foor SD; Acevedo MR; Walsh SA; Tricot G; Zhan F; Janz S
    Leukemia; 2016 Apr; 30(4):962-6. PubMed ID: 26202932
    [No Abstract]   [Full Text] [Related]  

  • 22. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
    Eischen CM; Woo D; Roussel MF; Cleveland JL
    Mol Cell Biol; 2001 Aug; 21(15):5063-70. PubMed ID: 11438662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Monoclonal gammopathies of undetermined significance called "MGUS"].
    Clément F
    Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.
    Ding JH; Yuan LY; Huang RB; Chen GA
    Eur J Haematol; 2014 Oct; 93(4):329-39. PubMed ID: 24766194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
    de La Coste A; Mignon A; Fabre M; Gilbert E; Porteu A; Van Dyke T; Kahn A; Perret C
    Cancer Res; 1999 Oct; 59(19):5017-22. PubMed ID: 10519417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monoclonal gammopathy of undetermined significance].
    Chaïbi P; Merlin L; Thomas C; Piette F
    Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Participation of the Bcl-2 and Fas molecules in experimental apoptosis of spleen B lymphocytes.
    Alvarado C; Alarcón-Riquelme ME; Alcocer-Varela J; Fernández C
    Rev Invest Clin; 1997; 49(3):171-8. PubMed ID: 9294959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset.
    Kuo P; Bynoe MS; Wang C; Diamond B
    Eur J Immunol; 1999 Oct; 29(10):3168-78. PubMed ID: 10540328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple myeloma: recognition and management.
    George ED; Sadovsky R
    Am Fam Physician; 1999 Apr; 59(7):1885-94. PubMed ID: 10208707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
    Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
    J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Bcl-2 in alpha beta T cell development in mice deficient in the common cytokine receptor gamma-chain: the requirement for Bcl-2 differs depending on the TCR/MHC affinity.
    Nakajima H; Leonard WJ
    J Immunol; 1999 Jan; 162(2):782-90. PubMed ID: 9916699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
    Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
    Bianchi G; Anderson KC
    CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgA orbital plasmacytoma in multiple myeloma.
    Hsu VJ; Agarwal MR; Chen CS; Rossi C
    Ophthalmic Plast Reconstr Surg; 2010; 26(2):126-7. PubMed ID: 20305517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiapoptotic molecule Bcl-2 is essential for the anabolic activity of parathyroid hormone in bone.
    Nagase Y; Iwasawa M; Akiyama T; Ogata N; Kadono Y; Nakamura M; Oshima Y; Yasui T; Matsumoto T; Masuda H; Bouillet P; Nakamura K; Tanaka S
    Ann N Y Acad Sci; 2010 Mar; 1192():330-7. PubMed ID: 20392256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.